Table 5.
Ingenuity Pathway Analysis of Genes Uniquely Detected in EV-Enriched Fractions 6 to 10.
| Ingenuity Canonical Pathways | Ratio | Molecules | p Value |
|---|---|---|---|
| Glucocorticoid biosynthesis | 0.50 | CYP11B1,CYP11B2,CYP17A1,CYP21A2 | 0.0001 |
| Intrinsic prothrombin activation pathway | 0.17 | F12,FGA,FGB,KLK11,KLK13,KLK4,KLK5 | 0.0005 |
| Mineralocorticoid biosynthesis | 0.43 | CYP11B1,CYP11B2,CYP21A2 | 0.0013 |
| Phototransduction pathway | 0.14 | ARR3,GNAT1,GUCA1A,GUCY2D,GUCY2F,OPN4,RHO | 0.0018 |
| Thyronamine and iodothyronamine metabolism | 0.67 | DIO1,DIO3 | 0.0035 |
| Thyroid hormone metabolism I (via deiodination) | 0.67 | DIO1,DIO3 | 0.0035 |
| SPINK1 pancreatic cancer pathway | 0.11 | CELA2A,KLK11,KLK13,KLK4,KLK5,PRSS3 | 0.0117 |
| Extrinsic prothrombin activation pathway | 0.19 | F12,FGA,FGB | 0.0166 |
| TR/RXR activation | 0.08 | DIO1,DIO3,FGA,G6PC,SYT12,THRSP,TRH | 0.0269 |
| Maturity onset diabetes of Young (MODY) signalling | 0.15 | GCK,PDX1,SLC2A2 | 0.0309 |
| Coagulation system | 0.11 | F12,FGA,FGB,SERPIND1 | 0.0324 |
| Basal cell carcinoma signalling | 0.09 | BMP15,FZD10,FZD7,FZD9,KIF7,WNT4 | 0.0347 |
| eNOS signaling | 0.07 | AQP12A/AQP12B,AQP2,AQP5,AQP8,CCNA1,CHRM1,CHRM3,CHRNA3,CHRNB3,CNGA4 | 0.0398 |
| Glycine betaine degradation | 0.20 | BHMT2,SARDH | 0.0447 |